The stock's fall snapped a three-day winning streak.

We recently compiled a list of the 10 Best Stocks to Buy According to Billionaire D.E. Shaw. In this article, we are going to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials ...

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of ...

On Friday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.05 which represents a decrease of $-1.47 or -1.48% from the prior close of $99.52. The stock opened at $98.83 and touched a ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...